Dr. Pagel on Challenges With ASCT in Relapsed/Refractory DLBCL

Publication
Video
Supplements And Featured PublicationsYear in Review: Updates in DLBCL Treatment
Volume 1
Issue 1

John M. Pagel, MD, PhD, discusses challenges with autologous stem cell transplant in relapsed/refractory diffuse large B-cell lymphoma.

John M. Pagel, MD, PhD, chief of the Hematologic Malignancies Program, and director, Hematopoietic Cell Transplantation Program, at Swedish Cancer Institute, discusses challenges with autologous stem cell transplant (ASCT) in relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

Approximately 40% of patients with DLBCL relapse, says Pagel. As such, more effective treatment options are needed for that subset of patients.

Currently, the standard of care for patients who relapse is ASCT, Pagel explains. Patients who relapse may need higher doses of treatment; however, intensive treatment can kill normal blood-forming cells in addition to remaining lymphoma cells.

Ultimately, ASCT, done safely through stem cell rescue, can be effective, but should not be considered a viable alternative for the majority of patients with relapsed/refractory DLBCL, Pagel concludes.

Related Videos
Neal Shore, MD, FACS, discusses current and ongoing research with radioligand therapy in patients with nonmetastatic castration-sensitive prostate cancer.
Jane L. Meisel, MD
Kari Wisinski, MD, Endowed Professor of Hematology and Oncology, chief, Division of Hematology, Medical Oncology, and Palliative Care, Department of Medicine, University of Wisconsin (UW) School of Medicine and Public Health; associate director, Clinical Research, co-lead, Breast Cancer Disease Oriented Team, UW Carbone Cancer Center
Susan C. Modesitt, MD, FACOG, FACS, professor, Department of Gynecology and Obstetrics, director, Division of Gynecologic Oncology, Department of Gynecology and Obstetrics, Emory University School of Medicine
Nikhil A. Gopal, MD
Hans C. Lee, MD
A panel of 4 experts on chronic graft-versus-host disease
A panel of 4 experts on chronic graft-versus-host disease
Manish A. Shah, MD